Acne

We are examining ways to change the treatment paradigm for people living with acne.

According to the American Academy of Dermatology, acne is the most common skin condition in the United States, affecting up to 50 million people of all ages.1 Acne affects 85 percent of teens and young adults, and even for older adults it is a top reason for dermatology office visits.

Because of the highly visible nature of acne, it can affect a person’s quality of life, resulting in social, psychological and emotional impairments. People with acne have reported an impact on their quality of life that is comparable to that expressed by patients with epilepsy, asthma, diabetes or arthritis.2

The formation of acne lesions is believed to result from an interaction of four physiological factors. These include:

  • Excessive sebum production (sebum is an oily substance made up of lipids, which is produced by glands in the skin called sebaceous glands)
  • Alternations in skin cells, which caluse clogged pores
  • Localized bacterial colonization
  • Inflammation

Download the Acne Infographic

No new, clinically meaningful therapies have been approved to treat acne in over a decade.

Most acne patients are treated with multiple topical therapies, which reduce the amount of dead skin cells and bacteria. These topical therapies are available by prescription or as over-the-counter treatment options; however, they have some limitations. There are currently no approved topical therapies that target excess sebum production, and there have been no new clinically meaningful therapies approved for acne treatments in more than a decade. Recent scientific advances in the understanding of the complex multi-factorial nature of this common disease offer an opportunity for scientific innovation through selective targeting of key elements of the disease process.

  • 1 Bickers et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology. 2006;55:490-500.
  • 2 Mallon et al., British Journal of Dermatology. April 1999.